Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$200.63 - $463.63
Previous CloseN/A
Volume47.78K
Average Volume (3M)324.78K
Market Cap
$9.86B
Enterprise Value$6.04B
Total Cash (Recent Filing)$802.02M
Total Debt (Recent Filing)$123.95M
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Oct 30, 2025EPS Estimate
-1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.90
Shares Outstanding22,289,015
10 Day Avg. Volume288,137
30 Day Avg. Volume324,780
Financial Highlights & Ratios
PEG Ratio-1.47
Price to Book (P/B)8.70
Price to Sales (P/S)36.44
P/FCF Ratio-14.36
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue11.72
Enterprise Value/Gross Profit12.21
Enterprise Value/Ebitda-22.65
Forecast
1Y Price Target
$483.08Price Target Upside10.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Bulls Say, Bears Say
Bulls Say
Market ExpansionMadrigal recently announced an in-licensing deal for exclusive global rights of SYH2086, an oral GLP-1RA, for the development of a combination therapy with Rezdiffra for MASH.
Market PerformanceRezdiffra has consistently outperformed Street expectations since its launch.
Regulatory ApprovalRezdiffra is now the first and only approved MASH therapy in Europe with labeling that does not specify a biopsy requirement for treatment.
Bears Say
Growth ProjectionsNear-term revenue estimates have been revised, lowering projected Rezdiffra U.S. product sales with a more modest growth rate for the rest of 2025 and 2026.
Market CompetitionSome investors are concerned about Rezdiffra losing market share to the more visible and popularized Wegovy treatment.
Pricing ConstraintsCost-conscious single payer systems in the EU may not reimburse Rezdiffra near its current annual Wholesale Acquisition Cost of approximately $49k.
Madrigal Pharmaceuticals News
MDGL FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest stock price was $200.63 and its highest was $463.63 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Madrigal Pharmaceuticals Inc’s market cap is $9.86B.
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Oct 30, 2025 which is in 22 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Aug 05, 2025. The company reported -$1.9 earnings per share for the quarter, beating the consensus estimate of -$3.554 by $1.654.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -1.97.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 22,289,015 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$1.9 in its last earnings report, beating expectations of -$3.554. Following the earnings report the stock price went up 8.587%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in MDGL
Madrigal Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$483.08 (10.73% Upside)
$483.08 (10.73% Upside)
Blogger Sentiment
Bullish
MDGL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 202.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $54.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.08%
12-Months-Change
Fundamentals
Return on Equity
-36.30%
Trailing 12-Months
Asset Growth
-7.67%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
MDGL Company Deck
MDGL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements such as strong revenue growth, patent extension, and international expansion plans. However, there were challenges like increased expenses and expected choppy gross to net dynamics. Overall, the positive developments and strategic advancements outweigh the challenges faced.View all MDGL earnings summariesMDGL Stock 12 Month Forecast
Average Price Target
$483.08
▲(10.73% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
BridgeBio Pharma
―
Revolution Medicines
―
Roivant Sciences
―
Ownership Overview
19.50% Insiders
25.31% Mutual Funds
<0.01% Other Institutional Investors
41.76% Public Companies and
Individual Investors